Table 4:

Crude and adjusted risk ratios of average monthly total standardized daily dose of selective serotonin reuptake inhibitors and falls – Medicare Current Beneficiary Surveys, 2010 −2017.

Sertraline vs Citalopram/escitalopram (reference)	Reported 1 or more falls vs No falls (reference)			Reported 2 or more falls vs No falls (reference)
	na	RRb	95% CIc	na	RRb	95% CIc
Overall
Crude	723	1.08	0.93–1.26	609	1.03	0.85–1.25
Adjustede	700	1.01	0.88–1.15	592	0.93	0.78–1.10
Low TSDD d
Crude	314	0.98	0.77–1.27	274	1.05	0.78–1.42
Adjustede	303	1.04	0.82–1.33	266	1.05	0.78–1.43
Medium TSDD d
Crude	184	1.18	0.85–1.62	146	1.17	0.75–1.83
Adjustede	175	1.14	0.84–1.55	139	1.15	0.81–1.62
High TSDD d
Crude	225	1.16	0.90–1.49	189	0.95	0.63–1.41
Adjustede	222	0.87	0.67–1.13	187	0.63	0.42–0.96

^an = sample size

^bRR = relative risk

^c95% CI = 95% confidence interval

^dTSDD = Average monthly total standardized daily dose categorized into low (60 or less), medium (60.1–90), and high (more than 90). For citalopram: Low TSDD is equivalent to ≤20 mg daily for 30 days; Medium TSDD is equivalent to >20 mg to 30 mg daily for 30 days; High TSDD is equivalent to >30 mg daily for 30 days. For escitalopram: Low TSDD is equivalent to ≤10 mg daily for 30 days; Medium TSDD is equivalent to >10 mg to 15 mg daily for 30 days; High TSDD is equivalent to >15 mg daily for 30 days. For Sertraline: Low TSDD is equivalent to ≤50 mg daily for 30 days; Medium TSDD is equivalent to >50 mg to 75 mg daily for 30 days; High TSDD is equivalent to >75 mg daily for 30 days.

^eAdjusted for demographic characteristics (age, sex, race), and health characteristics (self-reported health status, fall history, health conditions limited to diabetes, depression, stroke), and concurrent psychoactive medication use as mean number of medications during medication exposure window.